Abstract Body

Background: A recent surveillance study in 20 centers from 13 populous cities in Brazil reported a primary NNRTI resistance prevalence of 4.4%. Yet, a policy of universal genotype-resistance testing (GRT) prior to first-line ART initiation is not recommended by the Brazilian National AIDS Program guidelines. We sought to evaluate the cost-effectiveness of such a policy. Methodology: We used a previously published microsimulation model of HIV disease (CEPAC-International), populated with data from Brazil. We compared the clinical impact, costs, and cost-effectiveness of no initial genotype test to GRT, simulating both patients who did and did not have primary NNRTI resistance, and weighing the results based on primary resistance prevalence. Model parameters were derived from the HIV Clinical Cohort at the Evandro Chagas Clinical Research Institute of the Oswaldo Cruz Foundation and from published official Brazilian Governmental data: 69% were male, mean age 36 years (SD 10 years), mean CD4 348/μL (SD 300/μL), and a genotype cost of 2012 US$233. We assumed annual costs of US$2,200 for 2nd-line ART and US$12,750 to US$23,280 for 3rd- through 5th-line ART; these were varied broadly in sensitivity analyses. Costs were discounted at 3%/year. A strategy was defined as “very cost-effective” (or “cost-effective”) if its incremental cost-effectiveness ratio was less than 1x (or 3x), the 2012 Brazilian per capita GDP of US$12,340. Results: Compared to no initial genotype test, GRT increased discounted life-expectancy from 18.52 to 18.55 years and reduced discounted lifetime cost from US$98,100 to $97,000; thus, in the base case, GRT was cost-saving. GRT was cost-effective at primary resistance prevalences as low as 0.4% and remained cost-effective even when subsequent-line ART costs were assumed to be equal to second-line ART costs (ICER of US$14,290). Cost-inefficient results were observed only when simultaneously holding multiple parameters to extremes of their plausible ranges (Figure 1). Conclusions: This study is the first to demonstrate the attractiveness of GRT in a middle-income country with free-of-charge access to antiretroviral therapy. The cost of baseline genotype-resistance testing in ART-naive individuals in Brazil has the potential to improve survival and save money over the lifetime of the patient, as it reduces the need for more costly subsequent-line therapies. Initial genotype-resistance testing should be recommended by the Brazilian National Health System.